{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:24Z","timestamp":1790753784616,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3E1871-2"],"award-info":[{"award-number":["CMRPG3E1871-2"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12072-018-9890-x","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T04:14:00Z","timestamp":1533615240000},"page":"456-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study"],"prefix":"10.1007","volume":"12","author":[{"given":"Ming-Wei","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wey-Ran","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kung-Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7376-275X","authenticated-orcid":false,"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"key":"9890_CR1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221\u20131228","journal-title":"Science"},{"key":"9890_CR2","doi-asserted-by":"crossref","first-page":"e0169444","DOI":"10.1371\/journal.pone.0169444","volume":"12","author":"T Xing","year":"2017","unstructured":"Xing T, Xu H, Cao L, Ye M. HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLoS One 2017;12:e0169444","journal-title":"PLoS One"},{"key":"9890_CR3","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"HLY Chan","year":"2007","unstructured":"Chan HLY, Wong VWS, Tse AML, Tse CH, Chim AML, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462\u20131468","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9890_CR4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933\u20131944","journal-title":"Hepatology"},{"key":"9890_CR5","doi-asserted-by":"crossref","first-page":"e1000986","DOI":"10.1371\/journal.ppat.1000986","volume":"6","author":"H Wang","year":"2010","unstructured":"Wang H, Ryu W-S. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010;6:e1000986","journal-title":"PLoS Pathog"},{"key":"9890_CR6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4049\/jimmunol.0903874","volume":"185","author":"C Wei","year":"2010","unstructured":"Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010;185:1158\u20131168","journal-title":"J Immunol"},{"key":"9890_CR7","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis b virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215\u20134225","journal-title":"J Virol"},{"key":"9890_CR8","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","volume":"53","author":"A Schurich","year":"2011","unstructured":"Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494\u20131503","journal-title":"Hepatology"},{"key":"9890_CR9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.20649","volume":"41","author":"JN Stoop","year":"2005","unstructured":"Stoop JN, van der Molen RG, Baan CC, van der Laan LJW, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771\u2013778","journal-title":"Hepatology"},{"key":"9890_CR10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","volume":"10","author":"AW Thomson","year":"2010","unstructured":"Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010;10:753\u2013766","journal-title":"Nat Rev Immunol"},{"key":"9890_CR11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jmv.2165","volume":"66","author":"A Dahmen","year":"2002","unstructured":"Dahmen A, Herzog-Hauff S, B\u00f6cher WO, Galle PR, L\u00f6hr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002;66:452\u2013460","journal-title":"J Med Virol"},{"key":"9890_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/cgt.2012.61","volume":"19","author":"N Obeng-Adjei","year":"2012","unstructured":"Obeng-Adjei N, Choo DK, Saini J, Yan J, Pankhong P, Parikh A, et al. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther 2012;19:779\u2013787","journal-title":"Cancer Gene Ther"},{"key":"9890_CR13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2012.12.074","volume":"31","author":"P Buchmann","year":"2013","unstructured":"Buchmann P, Dembek C, Kuklick L, J\u00e4ger C, Tedjokusumo R, von Freyend MJ, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013;31:1197\u20131203","journal-title":"Vaccine."},{"key":"9890_CR14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","volume":"59","author":"D-Z Xu","year":"2013","unstructured":"Xu D-Z, Wang X-Y, Shen X-L, Gong G-Z, Ren H, Guo L-M, et al. Results of a phase III clinical trial with an HBsAg\u2013HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013;59:450\u2013456","journal-title":"J Hepatol"},{"key":"9890_CR15","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","volume":"32","author":"A Gaggar","year":"2014","unstructured":"Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 2014;32:4925\u20134931","journal-title":"Vaccine."},{"key":"9890_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(94)91384-6","volume":"344","author":"S Pol","year":"1994","unstructured":"Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994;344:342","journal-title":"Lancet"},{"key":"9890_CR17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1099\/0022-1317-82-2-367","volume":"82","author":"P Soussan","year":"2001","unstructured":"Soussan P, Pol S, Garreau F, Brechot C, Kremsdorf D. Vaccination of chronic hepatitis B virus carriers with preS2\/S envelope protein is not associated with the emergence of envelope escape mutants. J Gen Virol 2001;82:367","journal-title":"J Gen Virol"},{"key":"9890_CR18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91126-X","volume":"345","author":"Y-M Wen","year":"1995","unstructured":"Wen Y-M, Wu X-H, Hu D-C, Zhang Q-P, Guo S-Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995;345:1575\u20131576","journal-title":"Lancet."},{"key":"9890_CR19","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","volume":"3","author":"DZ Xu","year":"2008","unstructured":"Xu DZ, Zhao K, Guo LM, Chen XY, Wang HF, Zhang JM, et al. A randomized controlled phase IIb trial of antigen\u2013antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008;3:e2565","journal-title":"PLoS One"},{"key":"9890_CR20","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hep.24473","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;54:E1\u2013E9","journal-title":"Hepatology"},{"key":"9890_CR21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","volume":"64","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2014ANRS HB02 VAC-ADN. Gut 2015;64:139\u2013147","journal-title":"Gut"},{"key":"9890_CR22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","volume":"65","author":"AS Lok","year":"2016","unstructured":"Lok AS, Pan CQ, Han S-HB, Trinh HN, Fessel WJ, Rodell T, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 2016;65:509\u2013516","journal-title":"J Hepatol"},{"key":"9890_CR23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ng.348","volume":"41","author":"Y Kamatani","year":"2009","unstructured":"Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591\u2013595","journal-title":"Nat Genet"},{"key":"9890_CR24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24048","volume":"53","author":"X Guo","year":"2011","unstructured":"Guo X, Zhang Y, Li J, Ma J, Wei Z, Tan W, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011;53:422\u2013428","journal-title":"Hepatology"},{"key":"9890_CR25","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/liv.13405","volume":"37","author":"J Trinks","year":"2017","unstructured":"Trinks J, Nishida N, Hulaniuk ML, Caputo M, Tsuchiura T, Marciano S, et al. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. Liver Int 2017;37:1476\u20131487","journal-title":"Liver Int."},{"key":"9890_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jmv.10557","volume":"72","author":"Y-F Wu","year":"2004","unstructured":"Wu Y-F, Wang L-Y, Lee T-D, Lin HH, Hu C-T, Cheng M-L. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J Med Virol 2004;72:17\u201325","journal-title":"J Med Virol"},{"key":"9890_CR27","doi-asserted-by":"crossref","first-page":"e53008","DOI":"10.1371\/journal.pone.0053008","volume":"8","author":"H-R Cheng","year":"2013","unstructured":"Cheng H-R, Liu C-J, Tseng T-C, Su T-H, Yang H-I, Chen C-J, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013;8:e53008","journal-title":"PLoS One"},{"key":"9890_CR28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.12652","volume":"35","author":"T Hosaka","year":"2015","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Fukushima T, Kawamura Y, Sezaki H, et al. HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy. Liver Int 2015;35:1290\u20131302","journal-title":"Liver Int."},{"key":"9890_CR29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/apt.12910","volume":"40","author":"WP Brouwer","year":"2014","unstructured":"Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, et al. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2014;40:811\u2013818","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9890-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T07:00:44Z","timestamp":1539759644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9890-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["9890"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9890-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]}}}